Spero Therapeutics (SPRO) EBITDA (2016 - 2026)

Spero Therapeutics has reported EBITDA for 11 years, with the latest figure at -$7.5 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 48.83% year-over-year to -$7.5 million; the trailing twelve-month figure through Mar 2026 stood at $13.5 million (up 117.37% YoY), and the FY2025 full-year result was $6.3 million, up 108.61% from the prior year.
• EBITDA for Q1 2026 stood at -$7.5 million, down from $31.4 million in the prior quarter.
• The five-year high for EBITDA was $51.2 million in Q4 2023, with the low at -$32.8 million in Q1 2022.
• Historically, EBITDA has averaged -$6.0 million across 5 years, with a median of -$11.9 million in 2023.
• Annual changes were most pronounced in 2024 — EBITDA plunged 480.12% — and 2025, when it jumped 223.68%.
• Spero Therapeutics' EBITDA stood at $26.8 million in 2022, then jumped by 91.22% to $51.2 million in 2023, then plunged by 149.6% to -$25.4 million in 2024, then jumped by 223.68% to $31.4 million in 2025, then slumped by 124.0% to -$7.5 million in 2026.
• The last three EBITDA figures came in at -$7.5 million (Q1 2026), $31.4 million (Q4 2025), and -$7.9 million (Q3 2025), per Business Quant data.